Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 101,050 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 101,050 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00. Following the transaction, the director directly owned 308,504 shares in the company, valued at approximately $6,515,604.48. The trade was a 24.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.

Immunome Trading Up 9.9%

Immunome stock opened at $23.61 on Friday. The company has a 50-day moving average price of $20.96 and a 200 day moving average price of $21.78. Immunome, Inc. has a 12-month low of $7.96 and a 12-month high of $27.65. The stock has a market cap of $2.67 billion, a P/E ratio of -9.92 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.12. As a group, analysts forecast that Immunome, Inc. will post -2.06 EPS for the current year.

Institutional Trading of Immunome

Several institutional investors have recently added to or reduced their stakes in the stock. Pivotal bioVenture Partners Investment Advisor LLC purchased a new position in shares of Immunome during the third quarter worth $5,884,000. Nan Fung Trinity HK Ltd. raised its holdings in shares of Immunome by 20.7% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock valued at $15,349,000 after buying an additional 122,450 shares during the period. SG Americas Securities LLC raised its holdings in shares of Immunome by 1,749.3% in the 4th quarter. SG Americas Securities LLC now owns 162,168 shares of the company’s stock valued at $3,483,000 after buying an additional 153,399 shares during the period. Vanguard Group Inc. lifted its stake in Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after acquiring an additional 1,144,788 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Immunome during the 4th quarter worth about $3,652,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on IMNM. Leerink Partners lowered their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Barclays started coverage on Immunome in a research note on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target on the stock. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Truist Financial raised their price objective on Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Finally, Wedbush restated an “outperform” rating and issued a $31.00 price objective on shares of Immunome in a report on Friday, June 12th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.